Tian Q

Chia Tai-Tianqing Pharmaceutical (CTTQ) is a leading Chinese pharmaceutical company and a core subsidiary of Sino Biopharmaceutical. The company is a dominant player in the Chinese market for liver disease treatments and has rapidly expanded its portfolio into oncology, respiratory, and cardiovascular therapeutic areas. CTTQ is best known for developing and commercializing Anlotinib (Fukanghua), a multi-target tyrosine kinase inhibitor, and has a robust pipeline of innovative biologics and small molecules. With extensive R&D facilities in Nanjing and Lianyun-gang, the company integrates drug discovery, manufacturing, and large-scale commercialization to address significant unmet medical needs in China and globally.